Piernanda Vigliano1, Giovanni Battista Galloni1, Irene Bagnasco1, Giuliana Delia1, Alessandra Moletto1, Mauro Mana1, Samuele Cortese2,3. 1. Division of Child Neuropsychiatry, Martini Hospital, via Tofane 71, Torino, 10141, Italy. 2. Academic Unit of Psychology, Developmental Brain-Behaviour Laboratory, University of Southampton, Highfield Campus, Southampton, SO17 1BJ, UK. samuele.cortese@gmail.com. 3. New York University Child Study Center, One Park Ave, 7th floor, New York City, NY, 10016, USA. samuele.cortese@gmail.com.
Abstract
UNLABELLED: Children with ADHD may present with sleep disturbances that add to the impairment of the disorder. The long-term sleep effects of the first-line pharmacological treatment for ADHD, i.e., psychostimulants, are unclear. In this pilot study, we compared polysomnographic variables in children with ADHD (n = 11, aged 6-15 years), before pharmacological treatment, and in children without ADHD (n = 22, aged 5-14 years); we also assessed polysomnographic changes in children with ADHD (n = 7) after a 6-month treatment with methylphenidate immediate-release (once or twice daily). Compared to children without ADHD, those with ADHD at baseline presented with significantly increased duration of awakenings (p = 0.02), reduction in sleep efficiency (p = 0.03), and increase in stage I (N1) (p < 0.01) and reduction in stage II (N2) (p = 0.02) and stage III-IV (N3) percentages. Methylphenidate treatment did not significantly change any parameter of sleep architecture. CONCLUSION: Preliminary evidence from this pilot study shows that, compared to children without ADHD, those with ADHD presented a more fragmented and less effective sleep at baseline and that the 6-month methylphenidate treatment did not further negatively impact on sleep architecture. WHAT IS KNOWN: • Children with ADHD may present with subjectively reported and/or objectively confirmed disturbances of sleep. • The long-term effects on sleep of the first-line pharmacological treatment for ADHD, i.e., psychostimulants, are not clear. What is new: • Our study showed that the 6-month continuous treatment with methylphenidate did not further negatively impact on sleep architecture in children with ADHD.
UNLABELLED: Children with ADHD may present with sleep disturbances that add to the impairment of the disorder. The long-term sleep effects of the first-line pharmacological treatment for ADHD, i.e., psychostimulants, are unclear. In this pilot study, we compared polysomnographic variables in children with ADHD (n = 11, aged 6-15 years), before pharmacological treatment, and in children without ADHD (n = 22, aged 5-14 years); we also assessed polysomnographic changes in children with ADHD (n = 7) after a 6-month treatment with methylphenidate immediate-release (once or twice daily). Compared to children without ADHD, those with ADHD at baseline presented with significantly increased duration of awakenings (p = 0.02), reduction in sleep efficiency (p = 0.03), and increase in stage I (N1) (p < 0.01) and reduction in stage II (N2) (p = 0.02) and stage III-IV (N3) percentages. Methylphenidate treatment did not significantly change any parameter of sleep architecture. CONCLUSION: Preliminary evidence from this pilot study shows that, compared to children without ADHD, those with ADHD presented a more fragmented and less effective sleep at baseline and that the 6-month methylphenidate treatment did not further negatively impact on sleep architecture. WHAT IS KNOWN: • Children with ADHD may present with subjectively reported and/or objectively confirmed disturbances of sleep. • The long-term effects on sleep of the first-line pharmacological treatment for ADHD, i.e., psychostimulants, are not clear. What is new: • Our study showed that the 6-month continuous treatment with methylphenidate did not further negatively impact on sleep architecture in children with ADHD.
Authors: Samuele Cortese; Martin Holtmann; Tobias Banaschewski; Jan Buitelaar; David Coghill; Marina Danckaerts; Ralf W Dittmann; John Graham; Eric Taylor; Joseph Sergeant Journal: J Child Psychol Psychiatry Date: 2013-01-07 Impact factor: 8.982
Authors: Guilherme V Polanczyk; Erik G Willcutt; Giovanni A Salum; Christian Kieling; Luis A Rohde Journal: Int J Epidemiol Date: 2014-01-24 Impact factor: 7.196
Authors: Jiajun Lyu; Haifeng Li; Lei Wang; John A Groeger; Anna L Barnett; Jiajia Zhang; Wenchong Du; Jing Hua Journal: BMC Med Date: 2022-08-08 Impact factor: 11.150
Authors: Vidhi Kapoor; Raffaele Ferri; Mark A Stein; Chris Ruth; Jennifer Reed; Lourdes M DelRosso Journal: J Clin Sleep Med Date: 2021-04-01 Impact factor: 4.062
Authors: Ingrid Larsson; Katarina Aili; Jens M Nygren; Håkan Jarbin; Petra Svedberg Journal: Int J Environ Res Public Health Date: 2021-12-08 Impact factor: 3.390